Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
January 17, 2024 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the...
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
December 11, 2023 04:00 ET
|
AKAMPION
HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to tumor sitesPotent in vitro anti-tumor efficacy...
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
March 15, 2023 10:30 ET
|
iOmx Therapeutics AG
Discovery of novel immune checkpoints in the tumor microenvironment with iOTarg™ screening platformPredictive biomarker signature for lead product candidate OMX-0407 MUNICH, Germany, March 15, 2023 ...